[go: up one dir, main page]

FI83662B - Diagnostik antikropp och foerfarande foer dess framstaellning. - Google Patents

Diagnostik antikropp och foerfarande foer dess framstaellning. Download PDF

Info

Publication number
FI83662B
FI83662B FI812092A FI812092A FI83662B FI 83662 B FI83662 B FI 83662B FI 812092 A FI812092 A FI 812092A FI 812092 A FI812092 A FI 812092A FI 83662 B FI83662 B FI 83662B
Authority
FI
Finland
Prior art keywords
peptide
protein
antibodies
peptides
antigen
Prior art date
Application number
FI812092A
Other languages
English (en)
Finnish (fi)
Other versions
FI83662C (sv
FI812092L (fi
Inventor
Richard Alan Lerner
Nicola Nmi Green
J Gregor Sutcliffe
Thomas Michael Shinnick
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI83662(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI812092L publication Critical patent/FI812092L/fi
Application granted granted Critical
Publication of FI83662B publication Critical patent/FI83662B/fi
Publication of FI83662C publication Critical patent/FI83662C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (8)

1. Diagnostisk antikropp, som bildats och tagits till vara frän en värdorganism, som givits en effektiv mängd antigenpeptid eller -peptider, kännnetecknad därav, att anti-genpeptiden innehäller en aminosyrasekvens, som i huvudsak motsvarar en naturlig, till patogenen anslutande proteins antigenaminosyrasekvens, dä nämnda peptid är ansluten till en bärare och är given ät en animal värdorganism, som inducerar bildningen av antikroppar, som reagerar med till nämnda natur-liga patogen anslutna protein, och peptiden, frän vänster till höger och i riktningen frän ändaminogruppen till ändkarboxi-gruppen, har nägon av följande formler: (a) LeuThrGlnGlnPheHisGlnLeuLysProIleGluCysGluPro; (b) I1eLeuAsnArgLeuValGlnPheValLysAspArgI1eSerValValGlnAlaLeu VaiLeuThrGlnGlnPheHisGlnLeuLysProI1eGluCysGluPro; (c) PheProGlySerSerThrThrSerThrGlyProCysArgThrCysMetThrThrAla GlnGlyThrSerMetTyrProSerCys; (d) PheProGlySerSerThrThrSerThrGlyProCysArgThr; (e) GlnAspLeuProGlyAsnAspAsnAsnSerThrAlaThrLeuCysLeuGlyHisHis AiaValProAsnGlyThrLeuValLysThrl1eThrAsnAspGlnl1eGlu; (f) AsnAlaThrGluLeuValGlnSerSerSerThrGlyLysI1eCysAsnAsnProHis Argil eLeuAspGlylleAsnCys; (g) CysAsnAsnProHisArgI1eLeuAspGlyI1eAsnCysThrLeuI1eAspAlaLeu LeuGlyAspProHisCysAspGlyPheGlnAsnGluLysTrpAspLeuPhe; (h) AspTyrAlaSerLeuArgSerLeuValAlaSerSerGlyThrLeuGluPhel1eAsn GluGlyPheAsnTrpThrGlyValThrGlnAsnGlyGlySerSerAlaCys; (i) SerGlyLysValThrValSerThrLysArgSerGlnGlnThrl1 elleProAsnVal GlySerArgProTrpValArgGlyLeu; (j) CysProLysTyrValLysGlnAsnThrLeuLysLeuAlaThrGlyMetArgAsnVal ProGluLysGlnThrArg; (k) GlnAspLeuProGlyAsnAspAsnAsnSerThrAlaThrLeuCys; (l) CysLeuGlyHisHisAlaValProÄsnGlyThrLeuValLysThrI1eThrAsnAsp Gini1eGluValThrAsnAlaThrGluLeuValGlnSerSerSerThrGlyLysI1e Cys; 62 83 662 (m) CysAsnAsnProHisArgI1eLeuAspGly11eAsnCys; (n) CysAsnAsnProHisArgI1eLeu; (o) HisCysAspGlyPheGlnAsnGluLysTrpAspLeuPheValGlu; (p) HisCysAspGlyPheGlnAsnGluLysTrpAspLeuPheValGluArgSerLysAla PheSerAsnCyrTyrProTyrAspValProAspTyrAlaSerLeuArgSer; (q) ValThrGlnAsnGlyGlySerSerAlaCysLysArgGlyProAspSer; (r) CysLysArgGlyProAspSerLysArgGlyProAspSerGlyPhePheSerArgLeu AsnTrpLeuTyr; (s) CysLysArgGlyProAspSerLysArgGlyProAspSerGlyPhePheSerArgLeu AsnTrpLeuTyrLysSerGlySerTrpTyrProValGlnAsnValTrpMetProAsn AsnAspAsnSer; (t) AsnSerAspLysLeuTyrIleTrpGlyValHisHisProSerThrAspLysGluGln ThrAsnLeuTyrVal; (u) HisHisProSerThrAspLysGluGlnThrAsnLeuTyrVal; (v) AspProValThrThrThrValGluAsnTyrGlyGlyGluThrGlnlle; (w) AsnTyrGlyGlyGluThrGlnl1eGlnArgArgGlnHisThrAspVal; (x) GlnArgArgGlnHisThrAspValSerPhelleMetAspArgPheValLys; (y) ThrThrSerAlaGlyGluSerAlaAspProValThrThrThrValGluAsnTyr G1yGlyG1uThrG1nl1eG1nArgArgG1nHi sThrAspVa1SerPhe11eMet . . AspArgPheValLys; (z) CysLeuGlyGlnAsnSerGlnSerProThrSerAsnHisSerProThrSerAsnHis SerProThrSerCysProProThrCysProGlyTyrArgTrpMetCysLeuArgArg Phelle; (aa) GluAsnlleThrSerGlyPheLeuGlyProLeuLeuValLeuGln; (bb) LeuThrArglleLeuThrlleProGlnSerLeuAspSerTrp; (cc) SerLeuAsnPheLeuGlyGlyThrThrValCysLeuGlyGlnAsn; (dd) ValCysLeuGlyGlnAsn; (ee) LeuValLeuLeuAspTyrGlnGlyMetLeuProValCysProLeu; och (ff) vilken som heist peptid som innehäller ätminstone en minst sex aminosyror innehällande sekvens, vilka aminosyror angivits - i sekvenserna (a) - (ee).
2. Antikropp enligt patentkravet 1, kännetecknad därav, att peptiderna frän vänster tili höger och i riktning 63 83 662 frän ändaminogruppen till ändkarboxigruppen, motsvarar nägon av följande formler: (a) LeuThrGlnGlnPheHisGlnLeuLysProI1eGluCysGluPro; (b) IleLeuAsnArgLeuValGlnPheValLysAspArgIleSerValValGlnAlaLeu VaiLeuThrGlnGlnPheHisGlnLeuLysProI1eGluCysGluPro; (c) PheProGlySerSerThrThrSerThrGlyProCysArgThrCysMetThrThrAla GlnGlnThrSerMetTyrProSerCys; (d) PheProGlySerSerThrThrSerThrGlyProCysArgThr; (e) GlnAspLeuProGlyAsnAspAsnAsnSerThrAlaThrLeuCysLeuGlyHisHis AiaValProAsnGlyThrLeuValLysThrI1eThrAsnAspGlnl1eGlu; (f ) AsnAlaThrGluLeuValGlnSerSerSerThrGlyLys11eCysAsnAsnProHis ArgileLeuAspGlyl1eAsnCys; (g) CysAsnAsnProHisArgI1eLeuAspGlyl1eAsnCysThrLeuI1eAspAla LeuLeuGlyAspProHisCysAspGlyPheGlnAsnGluLysTrpAspLeuPhe; (h) AspTyrAlaSerLeuArgSereuValAiaSerSerGlyThrLeuGluPhel1eAsn GluGlyPheAsnTrpThrGlyValThrGlnAsnGlyGlySerSerAlaCys; (i) SerGlyLysVaiThrValSerThrLysArgSerGlnGlnThrFlel1eProAsnVal GlySerArgProTrpValArgGlyLeu; (j) CysProLysTyrValLysGlnAsnThrLeuLysLeuAlaThrGlyMetArgAsn ValProGluLysGlnThrArg, och (k) peptid som innehäller ätminstone en minst sex aminosyror innehallande sekvens, vilka syror valts bland sekvenserna (a) - (j).
3. Antikropp enligt patentkravet 1 eller 2, kanne- t e c k n a d därav, att den syntetiska peptiden är bunden tili en bärare.
4. Antikropp enligt patentkravet 4, kännetecknad därav, att bäraren är en lipidgrupp.
5. Antikropp enligt nägot av föregäende patentkrav, kännetecknad därav, att de syntetiska peptiderna är anslutna tili varandra som upprepande enheter. 64 83662
6. Antikropp enligt patentkravet 7, kännetecknad därav, att den i huvudsak innehäller tvä skilda syntetiska peptider enligt nägot av patentkravet 1 eller 2, vilka är anslutna till varandra som kopolymerer.
7. Antikropp enligt nägot av föregäende patentkrav, kännetecknad därav, att den i huvudsak innehäller en lipidrik kärngrupp, som innehäller flera syntetiska peptider enligt nägot av patentkraven 1-3, anslutna tili fettsyra-gruppen.
8. Förfarande för framstälIning av ett diagnostiskt anti-kroppspreparat, som efterliknar en antigendeterminant av ett naturligt, till animalpatogen anslutande protein, k ä n -netecknat därav, att (a) en bestämd mängd peptid syntetiseras kemiskt, vilken peptid inte innehäller (1) i naturen förekommande protein eller dess fragment, (2) konkurerande och störande proteiner, och (3) virala genomer, bakterienukleinsyror och endotoxiner, vilken peptid har ätminstone en fyra aminosyrors sekvens, som efterliknar en aminosyrasekvens av en antigen-determinant, som förekommer i naturligr, tili en patogen anslutande protein och vars molekylvikt är mindre än ett naturligt, tili patogen anslutande protein (b) antigenpeptiden binds kemiskt vid bararen för bildande av ett konjugat, (c) värdorganismen ges en sädan mängd kemiskt syntetiserad peptid, vilken mängd är tillräcklig för att inducera bildningen av antikroppar i värdorganismen, 11 65 8 3 6 62 (d) de sä bildade antikropparnas förmSga att reagera med de naturliga, tili animala patogenen anslutna proteinet och skydda värden analyseras, (e) större mängder än i steget (a) kemiskt syntetiserad peptid produceras, som inducerar antikroppar, vilka reagerar med naturligt till animalpatogen anslutande protein och skyddar värden, och (f) antikropparna tas tili vara frän värdorganismen.
FI812092A 1980-07-17 1981-07-02 Diagnostik antikropp och förfarande för dess framställning FI83662C (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16975880A 1980-07-17 1980-07-17
US16975880 1980-07-17
US20243180A 1980-10-30 1980-10-30
US20243180 1980-10-30
US24805981A 1981-03-27 1981-03-27
US24805981 1981-03-27

Publications (3)

Publication Number Publication Date
FI812092L FI812092L (fi) 1982-01-18
FI83662B true FI83662B (fi) 1991-04-30
FI83662C FI83662C (sv) 1991-08-12

Family

ID=27389709

Family Applications (1)

Application Number Title Priority Date Filing Date
FI812092A FI83662C (sv) 1980-07-17 1981-07-02 Diagnostik antikropp och förfarande för dess framställning

Country Status (15)

Country Link
EP (1) EP0044710B2 (sv)
KR (1) KR870000702B1 (sv)
AU (1) AU559234B2 (sv)
CA (1) CA1194794A (sv)
DE (1) DE3174241D1 (sv)
DK (1) DK318481A (sv)
ES (1) ES8305419A1 (sv)
FI (1) FI83662C (sv)
GR (1) GR74319B (sv)
IE (1) IE51410B1 (sv)
IL (1) IL63224A (sv)
NO (1) NO812341L (sv)
NZ (1) NZ197734A (sv)
PH (5) PH20629A (sv)
PT (1) PT73346B (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
DE3109696A1 (de) * 1981-03-13 1982-09-30 Gerhard Dr. med. 7800 Freiburg Hunsmann Verfahren zur herstellung eines als impfstoff geeigneten synthetischen peptids und es enthaltender impfstoff
DE3112338C2 (de) * 1981-03-28 1995-02-23 Klaus Von Der Helm Verwendung von Hybridisierungssonden zum Nachweis von HAV
EP0082789B1 (en) * 1981-12-22 1987-04-08 Baylor College of Medicine Immunological composition and method for hepatitis b virus
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
DE3382459D1 (de) * 1982-04-14 1991-12-19 James L Bittle Kuenstliches pikornavirusantigen.
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
ZA836080B (en) * 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
EP0105481A1 (en) * 1982-09-30 1984-04-18 The Wellcome Foundation Limited Novel antigens and vaccines containing them
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
JPS59501866A (ja) * 1982-10-11 1984-11-08 ナショナル・リサ−チ・ディベロップメント・コ−ポレイション 腸内ウイルスに対するワクチン接種に有用なポリペプチド
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
EP0162054B1 (en) * 1983-09-30 1991-03-06 Massachusetts Institute Of Technology Production of cdna representing hepatitis a viral sequences
US4615973A (en) * 1983-09-30 1986-10-07 The Rockefeller University Genetically engineered organisms expressing surface proteins of T. cruzi
US4777240A (en) * 1984-03-08 1988-10-11 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
AU579148B2 (en) * 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
GB8432401D0 (en) * 1984-12-21 1985-02-06 Bennett C E Liver fluke antigens
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
JP2702911B2 (ja) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US5066783A (en) * 1986-05-20 1991-11-19 Cohen Eric A Antiviral peptides and means for treating herpes infections
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
EP0300213A1 (en) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
EP0433276A1 (en) * 1987-07-06 1991-06-26 Peptide Technology Ltd Growth hormone related peptide
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5055396A (en) * 1987-11-03 1991-10-08 Scripps Clinic And Research Foundation Diagnostic methods and systems for quantifying apo ai
JPH02504395A (ja) * 1988-03-29 1990-12-13 スクリップス　クリニック　アンド　リサーチ　ファウンデーション アポａｉ定量のための診断方法及び診断システム
DE3911794A1 (de) * 1989-04-11 1990-10-18 Thomae Gmbh Dr K Monoklonale antikoerper gegen rekombinaten humanen gewebeplasminogenaktivator mit definierter epitopspezifitaet, deren herstellung und deren verwendung
IL95061A0 (en) * 1989-07-14 1991-06-10 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5387504A (en) * 1992-09-30 1995-02-07 Merck & Co., Inc. Monospecific antibodies and assay system for detecting stromelysin cleavage products
WO1994008597A1 (en) * 1992-10-14 1994-04-28 The Scripps Research Institute Methods for the detection of antigen-specific immune complexes
ES2065254B1 (es) * 1993-01-23 1995-07-16 Inmunologia & Genetica Aplic Peptidos y vacunas sinteticas contra parvovirus canino y otros virus relacionados.
US6632613B1 (en) * 1993-06-02 2003-10-14 University Of Utah Research Foundation Compositions and kits for fluorescence polarization assay of large molecules
WO1995015981A1 (en) * 1993-12-09 1995-06-15 University Of Utah Research Foundation Compositions and kits for fluorescence polarization assay of large molecules
WO1998029442A1 (en) * 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2818654A1 (en) * 2000-10-20 2002-04-25 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US7244580B2 (en) * 2001-11-08 2007-07-17 The Regents Of The University Of California Epsilon immunoglobulin chain derived peptides for induction of anti-IgE antibodies
EP2508596B1 (en) 2002-02-21 2015-08-12 Institute Of Virology MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4075194A (en) * 1976-12-09 1978-02-21 Yeda Research And Development Co., Ltd. Novel synthetic undecapeptide and clinical assay
NO158880C (no) * 1977-11-08 1988-11-09 Genentech Inc Fremgangsmaate for fremstilling av et spesifikt pattedyrhormon.
US4193915A (en) * 1978-04-13 1980-03-18 Mckerns Kenneth W Contraceptive, antibody generating, polypeptides
BR7908410A (pt) * 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
SE447263B (sv) * 1979-04-20 1986-11-03 Bonnierfoeretagen Ab Syntetisk, antigeniskt aktiv polypeptid och antigeniskt medel innehallande nemnda polypeptid
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses

Also Published As

Publication number Publication date
PH20603A (en) 1987-02-24
AU7283681A (en) 1982-01-21
GR74319B (sv) 1984-06-22
EP0044710B1 (en) 1986-04-02
IE51410B1 (en) 1986-12-24
FI83662C (sv) 1991-08-12
EP0044710B2 (en) 1991-02-06
IE811595L (en) 1982-01-17
PT73346A (en) 1981-08-01
CA1194794A (en) 1985-10-08
PH20598A (en) 1987-02-24
PH20629A (en) 1987-03-06
IL63224A (en) 1985-05-31
KR870000702B1 (ko) 1987-04-07
DE3174241D1 (en) 1986-05-07
KR830006423A (ko) 1983-09-24
EP0044710A1 (en) 1982-01-27
DK318481A (da) 1982-01-18
PH20133A (en) 1986-10-02
PT73346B (en) 1982-09-02
AU559234B2 (en) 1987-03-05
PH20597A (en) 1987-02-24
ES504033A0 (es) 1983-04-01
NZ197734A (en) 1985-05-31
IL63224A0 (en) 1981-10-30
FI812092L (fi) 1982-01-18
ES8305419A1 (es) 1983-04-01
NO812341L (no) 1982-01-18

Similar Documents

Publication Publication Date Title
FI83662B (fi) Diagnostik antikropp och foerfarande foer dess framstaellning.
US5665536A (en) Diagnastic method and test kit for the serological detection of the AIDS virus
JP2763408B2 (ja) Ｈｃｖに対する抗体の検出、ｈｃｖ感染の診断及びワクチンとしての予防に有用な合成ペプチド
EP0403568B1 (en) Synthetic peptide antigens for the detection of htlv-1 infection
CA1340735C (en) Htlv-iii envelope peptides
AU606928B2 (en) Synthetic peptide antigens for the detection of hiv-1 infection
EP0462627A1 (en) Antigens and peptides of lav.
EP0292454A2 (en) Synthetic peptide antigen for the detection of HIV-2 infection
EP0592026A1 (en) Method for determining antigenic reactivity in urine
WO1984003087A1 (en) Synthetic polypeptides from viral oncogenes
US5582968A (en) Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
AU606595B2 (en) HTLV-III/LAV virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against AIDS virus and diagnostic test for the serological detection of the AIDS virus
JP2650217B2 (ja) Ｈｔｌｖ―１感染の診断、治療及び予防接種のためのペプチド
US5061623A (en) Peptides comprising an immunogenic site of poliovirus and dnas containing nucleotide sequences coding for these peptides
US5476765A (en) Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines
JPH04507409A (ja) 風疹ｅ１ペプチド
US5283320A (en) Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom
JP2004535369A (ja) 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
GB2236754A (en) Peptide fragments of p17 protein of hiv
US5681696A (en) Synthetic peptide compositions with immunoreactivities to antibodies to HTLV
US5239056A (en) Peptide fractions which induce antibodies protecting against the bovine leukemia virus, a process for obtaining such fractions, their coding sequences and vaccines made from such fractions
CA1293188C (en) Composition of matter and method of immunizing against viral causative agents of aids and arc
CA1338028C (en) Synthetic peptide antigens for the detection of hiv-1 infection
US5198536A (en) Peptides comprising an immunogenic site of poliovirus and DNAs containing nucleotide sequences coding for these peptides
JPH04221398A (ja) 非ａ非ｂ型肝炎ウイルスに対する抗体と免疫化学反応するペプチド

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION